Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Featured trial
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

cabozantinib
transurethral resection of bladder tumor
neuropathy
carcinoma
protein/creatinine ratio
  • 0 views
  • 16 Feb, 2024
  • 1 location
Featured trial
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau)

We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective anti-tumour immune response with minimal systemic immune response and clinical toxicity.

  • 0 views
  • 14 Mar, 2022
  • 1 location
Featured trial
check theme  

check theme

  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

metastatic bladder cancer
metastatic bladder carcinoma
pembrolizumab
cancer chemotherapy
bladder tumor
  • 0 views
  • 16 Feb, 2024
  • 33 locations
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo.

  • 2 views
  • 05 Aug, 2020
Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy improves overall survival as compared with standard management in patients with limited metastatic urothelial bladder cancer and without progression following first-line systemic therapy. Each patient will be followed during 3 years from …

  • 2 views
  • 05 Aug, 2020
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen.

docetaxel
hormone level
intravesical bcg
hysterectomy
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …

measurable disease
small cell lung cancer
squamous cell carcinoma of head and neck
gastric cancer
ovarian ca
  • 0 views
  • 05 Aug, 2020
A Prospective Multi-centre Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up

Urothelial carcinoma (UC) is common malignancy and is considered to be one of the most expensive cancers. The traditional diagnostic methods of UC present with some shortcomings. For example, the specificity of CTU remains low while cystoscopy is invasive and expensive. Therefore, a noninvasive diagnostic method with high accuracy is …

urine cytology
cancer
transitional cell carcinoma
carcinoma
cystoscopy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Bladder cancer is often treated with cystectomy or radiation therapy. Following radiation therapy patients will often have severe side effects from the treatment.

androgen suppression
cancer radiation therapy
antiandrogen therapy
androgen deprivation therapy
androgen
  • 0 views
  • 16 Feb, 2024
  • 1 location